3 exciting ASX healthcare shares to buy in May

CSL Limited (ASX:CSL) and these ASX healthcare shares could be worth considering in May. Here's why I like them…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Due to a number of positive tailwinds including increased chronic disease burden and ageing populations, I believe the healthcare sector is one of the best places to invest your money with a long term view.

And the good news is that there's no shortage of options in the space for investors to choose from.

With that in mind, here are three options in the sector to consider:

Alcidion Group Ltd (ASX: ALC)

If you're interested in small cap shares then you might want to take a look at Alcidion. It is a fast-growing health informatics company which is aiming to transform healthcare with smart, intuitive technology solutions. It has a growing portfolio of software products and services that support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient outcomes.

CSL Limited (ASX: CSL)

And at the big end of the market you'll find this global biotherapeutics company. I believe CSL is the highest quality company Australia has to offer and capable of generating strong returns for investors over the long term. Especially given its leading therapies, lucrative plasma collection network, and its research and development pipeline. The latter is underpinned by high level of investment each year by the company. For example, in FY 2019 CSL invested a massive US$832 million in R&D activities across its businesses.

ResMed Inc. (ASX: RMD)

Finally, I think ResMed is another healthcare share to consider with a long term view. This medical device company has been growing at a very strong rate over the last few years thanks to its sleep treatment business. The proliferation of sleep apnoea has been driving very strong demand for both its hardware and its software. Given how many people globally are believed to be undiagnosed sufferers of sleep apnoea, I believe ResMed has a significant runway for growth. Though, with its third quarter update due to be released tomorrow, it might be prudent to wait for that before investing.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Alcidion Group Ltd and CSL Ltd. The Motley Fool Australia has recommended Alcidion Group Ltd and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

a man in a business suit points his finger amid a digitised map of the globe suspended in the air in front of him, complete with graphs, digital code and glyphs to indicate digital assets.
Investing Strategies

Future focus: How to diversify your portfolio with ASX AI ETFs

Looking for a simple and effective way to capitalise on the growth of AI technologies across global markets?

Read more »

chart showing an increasing share price
Growth Shares

Buy these excellent ASX growth shares for 15% to 20% returns

Analysts think big returns could be on the cards for owners of these shares.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Growth Shares

These ASX 200 growth shares could rise 12% to 30%

Analysts think big returns could be on offer from these shares.

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Growth Shares

Hoping to beat the ASX 200? I'd consider buying these 3 ASX shares

Analysts think these shares can outperform the market.

Read more »

a happy investor with a wide smile points to a graph that shows an upward trending share price
Growth Shares

5 top ASX growth shares to buy in April

Analysts think growth investors should be buying these shares.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Growth Shares

These mid-cap ASX shares could rise 20% to 50%

Goldman Sachs is tipping these stocks as buys.

Read more »

A happy boy with his dad dabs like a hero while his father checks his phone.
Growth Shares

2 ASX growth shares that could turn $1,000 into $10,000 by 2034

I think these two stocks have a shot at being 10-baggers.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Growth Shares

These top ASX 200 growth shares can rise 10% to 50%

Analysts see major upside ahead for these buy-rated shares.

Read more »